We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.75 | 9.50 | 10.00 | 9.75 | 9.75 | 9.75 | 10,208 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.98 | 16.97M |
From Apr 2019 to Apr 2024
TIDMSBTX
RNS Number : 1300F
SkinBioTherapeutics PLC
16 February 2018
SkinBioTherapeutics plc
Notice of interim results
Manchester, UK - 16 February 2018 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, will publish its interim results for the six months to 31 December 2017 on 21 February 2018.
The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company.
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468 Dr. Cath O'Neill, CEO 2760 Doug Quinn, CFO Cairn Financial Advisers Tel: +44 (0) 20 7213 LLP (Nominated Advisor) 0880 Tony Rawlinson / Emma Earl / Richard Nash Turner Pope Investments Tel: +44 (0) 20 3621 (Joint Broker) 4120 Ben Turner / James Pope Northland Capital (Joint Tel: +44 (0) 20 3861 Broker) 6625 John Howes / Tom Price Instinctif Partners Tel: +44 (0) 20 7457 Melanie Toyne-Sewell / 2020 Deborah Bell SkinBio@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Cath O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix PLC (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFIIFLIRLIT
(END) Dow Jones Newswires
February 16, 2018 05:02 ET (10:02 GMT)
1 Year Skinbiotherapeutics Chart |
1 Month Skinbiotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
